HALL NNP B-NP I-PATIENT
, , O I-PATIENT
NICK NNP B-NP I-PATIENT
65219816 CD O B-MEDICALRECORD
06/14/2097 CD O B-DATE
Primary JJ B-NP O
Care NNP I-NP O
Physician NNP I-NP O
: : O O
Youssef NNP B-NP B-DOCTOR
Nall NNP I-NP I-DOCTOR
, , O O
M.D. NNP B-NP O
Ludlow NNP B-NP B-HOSPITAL
Medical NNP I-NP I-HOSPITAL
Center NNP I-NP I-HOSPITAL
10 CD B-NP B-STREET
Wilder NNP I-NP I-STREET
St NNP I-NP I-STREET
Post NNP B-NP B-CITY
, , O O
IN IN B-PP B-STATE
86454 CD B-NP B-ZIP
Dear NNP B-NP O
Dr. NNP I-NP O
Nall NNP I-NP B-DOCTOR
: : O O
It PRP B-NP O
was VBD B-VP O
a DT B-NP O
pleasure NN I-NP O
to TO B-VP O
see VB I-VP O
Nick NNP B-NP B-PATIENT
again RB B-ADVP O
in IN B-PP O
the DT B-NP O
Internal NNP I-NP O
Medicine NNP I-NP O
at IN B-PP O
Wytheville NNP B-NP B-HOSPITAL
South NNP I-NP I-HOSPITAL
Hospital NNP I-NP I-HOSPITAL
on IN B-PP O
06/14/2098 CD B-NP B-DATE
for IN B-PP O
routine JJ B-NP O
folow NN I-NP O
up IN B-ADVP O
of IN B-PP O
radiation NN B-NP O
associated VBN B-VP O
ischemic IN B-PP O
heart NN B-NP O
disease NN I-NP O
. . O O
As IN B-SBAR O
you PRP B-NP O
know VBP B-VP O
, , O O
Nick NNP B-NP B-PATIENT
had VBD B-VP O
mantle JJ B-NP O
radiation NN I-NP O
in IN B-PP O
his PRP$ B-NP O
youth NN I-NP O
for IN B-PP O
Hodgkin NNP B-NP O
's POS B-NP O
lymphoma NN I-NP O
, , O O
and CC O O
subsequently RB B-VP O
had VBD I-VP O
2 CD B-NP O
NSTEMIs NN I-NP O
in IN B-PP O
2087 CD B-NP B-DATE
and CC I-NP O
2090 CD I-NP B-DATE
. . O O
He PRP B-NP O
received VBD B-VP O
bare-metal JJ B-NP O
stents NNS I-NP O
to TO B-PP O
his PRP$ B-NP O
LAD NN I-NP O
and CC O O
RCA NNP B-NP O
and CC O O
did VBD B-VP O
well RB B-ADVP O
until IN B-PP O
2094 CD B-NP B-DATE
when WRB B-ADVP O
after IN B-PP O
diagnosis NN B-NP O
and CC I-NP O
resection NN I-NP O
of IN B-PP O
a DT B-NP O
squamous JJ I-NP O
cell NN I-NP O
lung NN I-NP O
carcinoma NN I-NP O
, , O O
his PRP$ B-NP O
postop JJ I-NP O
course NN I-NP O
was VBD B-VP O
immediately RB I-VP O
complicated VBN I-VP O
by IN B-PP O
an DT B-NP O
acute JJ I-NP O
inferior JJ I-NP O
STEMI/VT/VF NNP I-NP O
arrest NN I-NP O
. . O O
Immediate NNP B-NP O
angiography NN I-NP O
post-resuscitation NN I-NP O
found VBD B-VP O
massive JJ B-NP O
thrombus NN I-NP O
burden NN I-NP O
in IN B-PP O
his PRP$ B-NP O
proximal JJ I-NP O
right JJ I-NP O
coronary JJ I-NP O
artery NN I-NP O
, , O O
with IN B-PP O
good JJ B-NP O
result NN I-NP O
after IN B-PP O
thrombectomy NN B-NP O
and CC I-NP O
POBA NNP I-NP O
, , O O
in IN B-PP O
addition NN B-NP O
to TO B-PP O
Integrilin NNP B-NP O
, , O O
aspirin NN B-NP O
, , O O
Plavix NNP B-NP O
, , O O
and CC O O
low JJ B-NP O
dose NN I-NP O
heparin NN I-NP O
. . O O
Remarkably RB B-ADVP O
, , O O
after IN B-PP O
an DT B-NP O
IABP NNP I-NP O
and CC I-NP O
aggressive JJ I-NP O
care NN I-NP O
Nick NNP B-NP B-PATIENT
walked VBD B-VP O
away RB B-ADVP O
with IN B-PP O
a DT B-NP O
preserved VBN I-NP O
LV NNP I-NP O
function NN I-NP O
after IN B-PP O
this DT B-NP O
event NN I-NP O
. . O O
He PRP B-NP O
did VBD B-VP O
well RB B-ADVP O
until IN B-PP O
01/2095 CD B-NP B-DATE
when WRB B-ADVP O
he PRP B-NP O
represented VBD B-VP O
with IN B-PP O
unstable JJ B-NP O
angina NN I-NP O
and CC O O
was VBD B-VP O
found VBN I-VP O
to TO I-VP O
have VB I-VP O
in-stent JJ B-NP O
restenosis NN I-NP O
in IN B-PP O
the DT B-NP O
ostial JJ I-NP O
LAD NN I-NP O
and CC O O
the DT B-NP O
ostial JJ I-NP O
RCA NNP I-NP O
bare-metal NN I-NP O
stents NNS I-NP O
. . O O
He PRP B-NP O
was VBD B-VP O
treated VBN I-VP O
with IN B-PP O
Cypher NNP B-NP O
drug-eluting NN I-NP O
stents NNS I-NP O
to TO B-PP O
both DT B-NP O
lesions NNS I-NP O
( -LRB- I-NP O
3.5 CD I-NP O
x NN I-NP O
18 CD B-NP O
mm CD I-NP O
Cypher NNP I-NP O
stent NN I-NP O
post NN I-NP O
dilated VBD B-VP O
to TO B-PP O
20 CD B-NP O
atm NN I-NP O
to TO B-PP O
the DT B-NP O
LAD NN I-NP O
and CC O O
3.5 CD B-NP O
x NN I-NP O
23 CD B-NP O
mm CD I-NP O
extending VBG B-VP O
slightly RB B-ADVP O
into IN B-PP O
the DT B-NP O
sinus NN I-NP O
of IN B-PP O
Valsalva NNP B-NP O
to TO B-PP O
the DT B-NP O
RCA NN I-NP O
) -RRB- I-NP O
with IN B-PP O
no DT B-NP O
residual JJ I-NP O
stenosis NN I-NP O
. . O O
Because IN B-PP O
of IN I-PP O
concerns NNS B-NP O
with IN B-PP O
regards NNS B-NP O
to TO B-PP O
recurrent JJ B-NP O
in-stent JJ I-NP O
restenosis NN I-NP O
he PRP B-NP O
was VBD B-VP O
put VBN I-VP O
on IN B-PP O
dual JJ B-NP O
antiplatelet NN I-NP O
therapy NN I-NP O
( -LRB- I-NP O
325mg JJ I-NP O
ECASA NNP I-NP O
and CC I-NP O
clopidogrel NN I-NP O
150 CD I-NP O
mg NN I-NP O
) -RRB- I-NP O
since IN B-PP O
that DT B-NP O
event NN I-NP O
intended VBD B-VP O
as IN B-PP O
longterm JJ B-NP O
therapy NN I-NP O
. . O O
He PRP B-NP O
has VBZ B-VP O
been VBN I-VP O
followed VBN I-VP O
by IN B-PP O
me PRP B-NP O
since IN B-PP O
2095 CD B-NP B-DATE
with IN B-PP O
no DT B-NP O
recurrent JJ I-NP O
ischemic JJ I-NP O
heart NN I-NP O
disease NN I-NP O
, , O O
chest NN B-NP O
pain NN I-NP O
, , O O
and CC O O
has VBZ B-VP O
returned VBN I-VP O
to TO B-PP O
normal JJ B-NP O
exercise NN I-NP O
capacity NN I-NP O
and CC B-PP O
with IN B-PP O
preserved JJ B-NP O
cardiac JJ I-NP O
systolic JJ I-NP O
function NN I-NP O
. . O O
Nick NNP B-NP B-PATIENT
continues VBZ B-VP O
to TO I-VP O
be VB I-VP O
very RB B-ADJP O
successful JJ I-ADJP O
as IN B-PP O
a DT B-NP O
technology NN I-NP B-PROFESSION
consultant NN I-NP I-PROFESSION
in IN B-PP O
IBM NNP B-NP B-ORGANIZATION
research NN I-NP I-ORGANIZATION
in IN B-PP O
Leland NNP B-NP B-CITY
. . O O
As IN B-SBAR O
the DT B-NP O
economy NN I-NP O
is VBZ B-VP O
picking VBG I-VP O
up RP B-PRT O
, , O O
his PRP$ B-NP O
work NN I-NP O
environment NN I-NP O
has VBZ B-VP O
improved VBN I-VP O
as RB B-ADVP O
has VBZ B-PP O
his PRP$ B-NP O
stress NN I-NP O
level NN I-NP O
. . O O
He PRP B-NP O
is VBZ B-VP O
walking VBG I-VP O
every DT B-NP O
day NN I-NP O
both DT O O
at IN B-PP O
work NN B-NP O
and CC O O
recreationally RB B-ADVP O
and CC O O
lost VBD B-VP O
another DT B-NP O
5pounds NNS I-NP O
. . O O
He PRP B-NP O
takes VBZ B-VP O
his PRP$ B-NP O
medications NNS I-NP O
regularly RB B-ADVP O
and CC O O
is VBZ B-VP O
usually RB B-ADVP O
compliant JJ B-ADJP O
but CC O O
ran VBD B-VP O
out IN B-ADVP O
of IN B-PP O
atenolol NN B-NP O
last JJ B-NP O
week NN I-NP O
and CC O O
instead RB B-VP O
has VBZ I-VP O
been VBN I-VP O
taking VBG I-VP O
bid NN B-NP O
ramipril NN I-NP O
in IN B-PP O
its PRP$ B-NP O
place NN I-NP O
. . O O
Every DT O O
year NN B-VP O
he PRP B-NP O
asks VBZ B-VP O
whether IN B-SBAR O
we PRP B-NP O
can MD B-VP O
down-titrate POS I-VP O
his PRP$ B-NP O
clopidogrel NN I-NP O
both CC O O
for IN B-PP O
tolerance NN B-NP O
and CC I-NP O
cost NN I-NP O
reasons NNS I-NP O
( -LRB- O O
I PRP B-NP O
reassured VBD B-VP O
him PRP B-NP O
that IN B-SBAR O
it PRP B-NP O
should MD B-VP O
be VB I-VP O
generic JJ B-ADJP O
within IN B-PP O
a DT B-NP O
year NN I-NP O
) -RRB- I-NP O
. . O O
Nevertheless RB B-ADVP O
, , O O
we PRP B-NP O
tested VBD B-VP O
the DT B-NP O
degree NN I-NP O
of IN B-PP O
platelet NN B-NP O
inhibition IN B-PP O
he PRP B-NP O
currently RB B-ADVP O
has VBZ B-VP O
with IN B-PP O
the DT B-NP O
VerifyNow NNP I-NP O
P2Y12 NNP I-NP O
PRU NNP I-NP O
assay NN I-NP O
, , O O
and CC O O
his PRP$ B-NP O
result NN I-NP O
was VBD B-VP O
177 CD B-NP O
, , O O
which WDT B-NP O
is VBZ B-VP O
below IN B-PP O
the DT B-NP O
cut-off NN I-NP O
of IN B-PP O
230 CD B-NP O
PRU NNP I-NP O
thought VBD B-VP O
to TO B-PP O
approximate JJ B-NP O
adequate JJ I-NP O
platelet NN I-NP O
inhibition NN I-NP O
. . O O
He PRP B-NP O
recently RB B-ADVP O
had VBD B-VP O
some DT B-NP O
transient JJ I-NP O
melena NN I-NP O
for IN B-PP O
which WDT B-NP O
he PRP B-NP O
was VBD B-VP O
placed VBN I-VP O
on IN B-PP O
ranitidine NN B-NP O
. . O O
His PRP$ B-NP O
current JJ I-NP O
medications NNS I-NP O
should MD B-VP O
be VB I-VP O
aspirin RB B-NP O
325 CD I-NP O
mg JJ I-NP O
p.o NN I-NP O
. . O O
daily RB B-ADVP O
, , O O
clopidogrel NN B-NP O
150 CD I-NP O
mg NN I-NP O
p.o RB B-ADVP O
. . O O
daily JJ B-ADVP O
, , O O
atorvastatin IN B-SBAR O
80 CD B-NP O
mg JJ I-NP O
p.o NN I-NP O
. . O O
daily RB B-ADVP O
, , O O
ramipril NNP B-NP O
10 CD I-NP O
mg NN I-NP O
p.o NN I-NP O
. . O O
daily RB B-ADVP O
, , O O
atenolol IN B-PP O
50 CD B-NP O
mg JJ I-NP O
p.o NN I-NP O
. . O O
daily RB B-ADVP O
, , O O
L-thyroxine NNP B-NP O
125 CD I-NP O
mcg JJ I-NP O
p.o NN I-NP O
. . O O
daily RB B-ADVP O
, , O O
ranitidine NNP B-NP O
150 CD I-NP O
mg NN I-NP O
po NN I-NP O
daily RB B-ADVP O
, , O O
1 CD B-NP O
tablet NN I-NP O
fish NN I-NP O
oil NN I-NP O
daily JJ I-NP O
, , O O
and CC O O
1 CD B-NP O
tablet NN I-NP O
of IN B-PP O
vitamin NN B-NP O
D NNP I-NP O
daily RB B-ADVP O
. . O O
He PRP B-NP O
has VBZ B-VP O
no RB I-VP O
known VBN I-VP O
drug NN B-NP O
allergies NNS I-NP O
. . O O
Physical JJ B-NP O
Examination NNP I-NP O
: : O O
Nick NNP B-NP B-PATIENT
looks VBZ B-VP O
well RB B-ADVP O
. . O O
He PRP B-NP O
is VBZ B-VP O
in IN B-PP O
no DT B-NP O
distress NN I-NP O
. . O O
Weight NNP B-NP O
is VBZ B-VP O
221 CD B-NP O
lbs NNS I-NP O
. . O O
Blood NN B-NP O
pressure NN I-NP O
is VBZ B-VP O
150/8 CD B-NP O
0 CD I-NP O
in IN B-PP O
the DT B-NP O
right JJ I-NP O
arm NN I-NP O
repeated VBN B-VP O
over IN B-PP O
3 CD B-NP O
manual NN I-NP O
measurements NNS I-NP O
with IN B-PP O
a DT B-NP O
large JJ I-NP O
manual NN I-NP O
cuff NN I-NP O
and CC O O
his PRP$ B-NP O
heart NN I-NP O
rate NN I-NP O
is VBZ B-VP O
70 CD B-NP O
and CC I-NP O
regular JJ I-NP O
. . O O
His PRP$ B-NP O
head NN I-NP O
and CC I-NP O
neck NN I-NP O
exam NN I-NP O
revealed VBD B-VP O
normal JJ B-ADJP O
jugular RB B-NP O
venous JJ I-NP O
pressure NN I-NP O
, , O O
normal JJ B-NP O
carotid NN I-NP O
upstroke NN I-NP O
and CC I-NP O
contour NN I-NP O
with IN B-PP O
no DT B-NP O
bruits NNS I-NP O
. . O O
His PRP$ B-NP O
chest NN I-NP O
is VBZ B-VP O
clear JJ B-ADJP O
to TO B-PP O
auscultation NN B-NP O
. . O O
His PRP$ B-NP O
cardiovascular JJ I-NP O
exam NN I-NP O
demonstrated VBD B-VP O
normal JJ B-NP O
left JJ I-NP O
apex NN I-NP O
and CC O O
normal JJ B-NP O
first JJ I-NP O
and CC I-NP O
second JJ I-NP O
heart NN I-NP O
sounds VBZ B-VP O
with IN B-PP O
a DT B-NP O
normal JJ I-NP O
splitting NN I-NP O
of IN B-PP O
the DT B-NP O
second JJ I-NP O
heart NN I-NP O
sound NN I-NP O
with IN B-PP O
no DT B-NP O
additional JJ I-NP O
gallops NNS I-NP O
, , O O
rubs NNS B-NP O
, , O O
or CC O O
murmurs NNS B-NP O
. . O O
He PRP B-NP O
had VBD B-VP O
no DT B-NP O
peripheral JJ I-NP O
edema NN I-NP O
. . O O
His PRP$ B-NP O
abdomen NN I-NP O
is VBZ B-VP O
soft JJ B-ADJP O
and CC O O
nontender NN B-NP O
with IN B-PP O
no DT B-NP O
organomegaly NN I-NP O
. . O O
He PRP B-NP O
had VBD B-VP O
2+ JJ B-NP O
pulses NNS I-NP O
in IN B-PP O
the DT B-NP O
peripheral JJ I-NP O
exam NN I-NP O
. . O O
EKG NN B-NP O
today NN I-NP O
demonstrated VBD B-VP O
sinus IN B-PP O
rhythm NN B-NP O
at IN B-PP O
88 CD B-NP O
bpm NN I-NP O
with IN B-PP O
voltage NN B-NP O
criteria NNS I-NP O
for IN B-PP O
LVH NNP B-NP O
, , I-NP O
LAE NNP I-NP O
and CC I-NP O
prior RB I-NP O
inferior JJ I-NP O
Q-waves NNS I-NP O
. . O O
We PRP B-NP O
are VBP B-VP O
awaiting VBG I-VP O
an DT B-NP O
updated VBN I-NP O
lipid NN I-NP O
profile NN I-NP O
due RB B-ADVP O
this DT B-NP O
week NN I-NP O
before IN B-PP O
modifying VBG B-VP O
his PRP$ B-NP O
lipid JJ I-NP O
therapy NN I-NP O
which WDT B-NP O
is VBZ B-VP O
aimed VBN I-VP O
to TO I-VP O
target VB I-VP O
a DT B-NP O
goal NN I-NP O
of IN B-PP O
less JJR B-NP O
than IN I-NP O
70 CD I-NP O
mg/dL NN I-NP O
. . O O
He PRP B-NP O
has VBZ B-VP O
tried VBN I-VP O
and CC I-VP O
failed VBN I-VP O
a DT B-NP O
trial NN I-NP O
of IN B-PP O
niacin NN B-NP O
in IN B-PP O
the DT B-NP O
past NN I-NP O
due JJ B-ADJP O
to TO B-PP O
intolerable JJ B-NP O
flushing NN I-NP O
and CC I-NP O
headache NN I-NP O
. . B-PP O
His PRP$ B-NP O
LDL NNP I-NP O
last JJ B-NP O
year NN I-NP O
was VBD B-VP O
98 CD B-NP O
mg/dL NN I-NP O
though IN B-NP O
HDL NNP B-NP O
has VBZ B-VP O
improved VBN I-VP O
to TO B-PP O
37 CD B-NP O
mg/dL NN I-NP O
. . B-PP O
His PRP$ B-NP O
TC/HDL NNP I-NP O
ratio NN I-NP O
is VBZ B-VP O
4.2 CD B-NP O
, , O O
his PRP$ B-NP O
TC NNP I-NP O
is VBZ B-VP O
155 CD B-NP O
mg/dL NN I-NP O
, , O O
and CC O O
TG NNP B-NP O
101 CD I-NP O
mg/dL NN I-NP O
. . O O
HbA1c '' O O
is VBZ B-VP O
7.2 CD B-NP O
% NN I-NP O
. . O O
The DT B-NP O
previous JJ I-NP O
echo NN I-NP O
in IN B-PP O
2096 CD B-NP B-DATE
demonstrated VBD B-VP O
normal JJ B-NP O
LV NN I-NP O
size NN I-NP O
and CC I-NP O
function NN I-NP O
with IN B-PP O
a DT B-NP O
normal JJ I-NP O
LV NN I-NP O
ejection NN I-NP O
fraction NN I-NP O
of IN B-PP O
60%-65 CD B-NP O
% NN I-NP O
with IN B-PP O
no DT B-NP O
signs NNS I-NP O
of IN B-PP O
LVH. NNP B-NP O
Impression NN B-NP O
: : O O
Nick NNP B-NP B-PATIENT
is VBZ B-VP O
doing VBG I-VP O
well RB B-ADVP O
with IN B-PP O
CCS NNP B-NP O
1 CD I-NP O
symptoms NNS I-NP O
after IN B-PP O
repeated VBN B-NP O
MIs NNS I-NP O
most RBS B-ADVP O
recently RB I-ADVP O
in IN B-PP O
2095 CD B-NP B-DATE
due JJ B-ADJP O
to TO B-PP O
accelerated VBN B-NP O
coronary JJ I-NP O
atheroclerosis NN I-NP O
and CC I-NP O
radiation NN I-NP O
stenoses NNS I-NP O
. . O O
To TO B-VP O
target VB I-VP O
his PRP$ B-NP O
coronary JJ I-NP O
risk NN I-NP O
factors NNS I-NP O
, , O O
I PRP B-NP O
recommended VBD B-VP O
the DT B-NP O
following NN I-NP O
: : O O
1 LS O O
. . B-NP O
Should NNP B-PP O
his PRP$ B-NP O
LDL NNP I-NP O
be VB B-VP O
&gt RB B-ADVP O
;70mg/dL IN B-SBAR O
he PRP B-NP O
should MD B-VP O
switch VB I-VP O
to TO B-PP O
rosuvastatin NNP B-NP O
40mg CD I-NP O
daily JJ I-NP O
for IN B-PP O
LDL NNP B-NP O
and CC I-NP O
HDL NNP I-NP O
improvement NN I-NP O
. . O O
2. DT B-NP O
Given VBN I-NP O
clopidorel NN I-NP O
platelet NN I-NP O
reactivity NN I-NP O
is VBZ B-VP O
less JJR B-NP O
than IN I-NP O
230 CD I-NP O
PRU NNS I-NP O
he PRP B-NP O
will MD B-VP O
decrease VB I-VP O
to TO B-PP O
75 CD B-NP O
mg NN I-NP O
daily RB B-ADVP O
and CC O O
we PRP B-NP O
will MD B-VP O
re-check VB I-VP O
his PRP$ B-NP O
PRU NNP I-NP O
activity NN I-NP O
after IN B-PP O
at IN B-NP O
least JJS I-NP O
7 CD I-NP O
days NNS I-NP O
on IN B-PP O
this DT B-NP O
dose NN I-NP O
. . O O
Should MD B-VP O
PRU NNP B-NP O
&gt JJ I-NP O
; : O O
230 CD B-NP O
he PRP B-NP O
will MD B-VP O
either RB I-VP O
need VB I-VP O
to TO I-VP O
restart VB I-VP O
150 CD B-NP O
mg JJ I-NP O
daily JJ I-NP O
and CC O O
take VB B-VP O
a DT B-NP O
PPI NNP I-NP O
like IN B-PP O
pantoprazole NN B-NP O
or CC I-NP O
switch NN I-NP O
to TO B-VP O
prasugrel VB I-VP O
( -LRB- B-NP O
or CC O O
when WRB B-ADVP O
available JJ B-NP O
ticagrelor NN I-NP O
) -RRB- I-NP O
. . O O
3. . O O
He PRP B-NP O
will MD B-VP O
continue VB I-VP O
a DT B-NP O
healthy JJ I-NP O
heart NN I-NP O
diet NN I-NP O
and CC O O
exercise NN B-NP O
and CC O O
we PRP B-NP O
will MD B-VP O
see VB I-VP O
him PRP B-NP O
again RB B-ADVP O
in IN B-PP O
6 CD B-NP O
months NNS I-NP O
. . O O
Thank VB B-VP O
you PRP B-NP O
for IN B-PP O
allowing VBG B-VP O
me PRP B-NP O
to TO B-VP O
participate VB I-VP O
in IN B-PP O
his PRP$ B-NP O
care NN I-NP O
. . O O
As IN B-SBAR O
I PRP B-NP O
am VBP B-VP O
not RB I-VP O
continuing VBG I-VP O
a DT B-NP O
general JJ I-NP O
out-patient JJ I-NP O
clinic NN I-NP O
next JJ B-NP O
year NN I-NP O
, , O O
Nick NNP B-NP B-PATIENT
will MD B-VP O
transition NN B-NP O
to TO B-PP O
another DT B-NP O
cardiologist NN I-NP O
who WP B-NP O
can MD B-VP O
accomodate VB I-VP O
his PRP$ B-NP O
day NN I-NP O
off RP I-NP O
from IN B-PP O
work NN B-NP O
which WDT B-NP O
is VBZ B-VP O
typically RB B-ADVP O
on IN B-PP O
Saturday NNP B-NP B-DATE
. . O O
The DT B-NP O
patient NN I-NP O
was VBD B-VP O
discussed VBN I-VP O
in IN B-PP O
clinic NN B-NP O
with IN B-PP O
Dr. NNP B-NP O
Neale NNP I-NP B-DOCTOR
Xiao NNP I-NP I-DOCTOR
who WP B-NP O
agreed VBD B-VP O
with IN B-PP O
this DT B-NP O
plan NN I-NP O
. . O O
Yours PRP B-NP O
sincerely RB B-ADVP O
, , O O
Dictated VBN B-VP O
by IN B-PP O
: : O O
Yisroel NNP B-NP B-DOCTOR
F NNP I-NP I-DOCTOR
Cooley NNP I-NP I-DOCTOR
, , O O
MD NNP B-NP O
MPH NNP I-NP O
FRCPC NNP I-NP O
Email NN B-NP O
: : O O
yfcooley@wsh NN B-NP I-EMAIL
.org . O I-EMAIL
